VET CELL TECH Spółka z Ograniczoną Odpowiedzialnością (KRS 0001026396, NIP 6762639198) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. VET CELL TECH operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since March 21, 2023. VET CELL TECH's most recently reported net revenue was 72.3 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - VET CELL TECH
Identity
- Name
- VET CELL TECH Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- March 21, 2023
- Registry status as of
- July 13, 2026
- Latest entry
- July 13, 2026
- Founding act
- 16.03.2023
Articles of association history (4)
- March 16, 2023: 16.03.2023
- 5 MAJA 2023, REP A NR 2325/2023, NOTARIUSZ TOMASZ GŁÓWKA, KANCELARIA NOTARIALNA W WIELICZCE, ZMIANA PAR 9
- June 15, 2023: 15.06.2023, REP A NUMER 4197/2023, NOTARIUSZ MAGDALENA MISZALSKA-ZAPAŁA, KANCELARIA NOTARIALNA W NIEPOŁOMICACH, PRZYJĘCIE NOWEGO BRZMIENIA UMOWY SPÓŁKI
- May 12, 2025: 12.05.2025, REP A NUMER 4234/2025, NOTARIUSZ MAGDALENA MISZALSKA-ZAPAŁA, KANCELARIA NOTARIALNA W NIEPOŁOMICACH, DODANIE DO PAR 1 NOWEGO UST. 3, ZMIANA PAR 6 UST 1 ORAZ PAR 7
Activities
Main activity
72.10.ZScientific research and development
Other activities
Address and contact
- Address
- UL. PROFESORA MICHAŁA BOBRZYŃSKIEGO, 14, 30-348, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- KONTAKT@VETCELLTECH.COM
- Website
WWW.VETCELLTECH.COM- E-delivery address
- AE:PL-87122-26961-BBEAS-19
Risk and payment profile - VET CELL TECH
Credibility rating
35.9 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
29
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany właścicieli. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
2
2/3 yrs
Board changes
0
0/3 yrs
PKD changes
1
1/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: E (36/100)
Trend: deteriorating (-6.8 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2023–2024
Current: 1.8 K PLN
Safe: 358.65 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - VET CELL TECH
Founded
March 21, 2023
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
63.3 K PLN
1,034 shares total
Shareholders
4
shareholders
Board
3 people
Sup. board: 7
Filed years
2 years
2023–2024 · profitable: 0/2
Registry entries
15
latest: July 13, 2026
Risk signals
Revenue
72.3 K PLN
2024
Net profit
-1.5 M PLN
2024
Assets
8.0 M PLN
2024
Equity
6.2 M PLN
2024
Valuation
3.2 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - VET CELL TECH.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
